53 research outputs found
The molecular mechanism of action of the antiangiogenic natural product, cremastranone
Indiana University-Purdue University Indianapolis (IUPUI)Prevention of pathological angiogenesis is a key strategy for treatment of
common blinding ocular diseases such as retinopathy of prematurity, proliferative
diabetic retinopathy, and wet age-related macular degeneration. The current
treatment strategies are associated with partial vision loss and are ineffective in a
significant patient population. Hence novel drugs as well as new ways to target
ocular angiogenesis are needed for treating these diseases. I pursued a natural
antiangiogenic compound, cremastranone, to develop novel drug leads and to
find new targets. The objective of my doctoral thesis project was to elucidate
cremastranone’s molecular mechanism of action and optimize its structureactivity
relationship (SAR).
In order to achieve this goal, with the help of chemistry collaborators
cremastranone was synthesized for the first time. I showed that cremastranone
has 50-fold more potency against endothelial cells as compared to nonendothelial
cells, and also tested a novel active isomer, SH-11052. By SAR
studies I identified a potent molecule, SH-11037, that has 10-fold more selectivity
against retinal endothelial cells as compared to macrovascular endothelial cells. I
then elucidated cremastranone’s molecular mechanism using a chemical
proteomic approach. I identified ferrochelatase (FECH) as a specific interacting
protein partner of cremastranone using photoaffinity chromatography. Hence, I hypothesized that cremastranone exerts its antiangiogenic activities through
modulation of the functions of FECH.
Cremastranone inhibited the enzymatic activity FECH in endothelial cells.
Therefore, I investigated the role of FECH in ocular angiogenesis. Partial loss of
FECH, using a siRNA-based knock down approach, decreased retinal
angiogenesis both in vitro and in vivo in mouse models. Knock down of FECH
decreased the expression levels of key proangiogenic proteins HIF-1α, eNOS,
and VEGFR2. This work suggests that ferrochelatase plays an important,
previously undocumented role in angiogenesis and that targeting of this enzyme
by cremastranone might be exploited to inhibit pathological angiogenesis in
ocular diseases
Natural product inhibitors of ocular angiogenesis
Natural products are characterized by high chemical diversity and biochemical specificity; therefore, they are appealing as lead compounds for drug discovery. Given the importance of angiogenesis to many pathologies, numerous natural products have been explored as potential anti-angiogenic drugs. Ocular angiogenesis underlies blinding eye diseases such as retinopathy of prematurity (ROP) in children, proliferative diabetic retinopathy (DR) in adults of working age, and age-related macular degeneration (AMD) in the elderly. Despite the presence of effective therapy in many cases, these diseases are still a significant health burden. Anti-VEGF biologics are the standard of care, but may cause ocular or systemic side effects after intraocular administration and patients may be refractory. Many anti-angiogenic compounds inhibit tumor growth and metastasis alone or in combination therapy, but a more select subset of them has been tested in the context of ocular neovascular diseases. Here, we review the promise of natural products as anti-angiogenic agents, with a specific focus on retinal and choroidal neovascularization. The multifunctional curcumin and the chalcone isoliquiritigenin have demonstrated promising anti-angiogenic effects in mouse models of DR and choroidal neovascularization (CNV) respectively. The homoisoflavanone cremastranone and the flavonoid deguelin have been shown to inhibit ocular neovascularization in more than one disease model. The isoflavone genistein and the flavone apigenin on the other hand are showing potential in the prevention of retinal and choroidal angiogenesis with long-term administration. Many other products with anti-angiogenic potential in vitro such as the lactone withaferin A, the flavonol quercetin, and the stilbenoid combretastatin A4 are awaiting investigation in different ocular disease-relevant animal models. These natural products may serve as lead compounds for the design of more specific, efficacious, and affordable drugs with minimal side effects
The First Synthesis of the Antiangiogenic Homoisoflavanone, Cremastranone
An antiangiogenic homoisoflavanone, cremastranone, was synthesized for the first time. This scalable synthesis, which includes selective demethylation, could be used to develop lead molecules to treat angiogenesis-induced eye diseases. Synthetic cremastranone inhibited the proliferation, migration and tube formation ability of human retinal microvascular endothelial cells, important steps in pathological angiogenesis
Design, synthesis and biological evaluation of photoaffinity probes of antiangiogenic homoisoflavonoids
A naturally occurring homoisoflavonoid, cremastranone (1) inhibited angiogenesis in vitro and in vivo. We developed an analogue SH-11037 (2) which is more potent than cremastranone in human retinal microvascular endothelial cells (HRECs) and blocks neovascularization in animal models. Despite their efficacy, the mechanism of these compounds is not yet fully known. In the course of building on a strong foundation of SAR and creating a novel chemical tool for target identification of homoisoflavonoid-binding proteins, various types of photoaffinity probes were designed and synthesized in which benzophenone and biotin were attached to homoisoflavanonoids using PEG linkers on either the C-3′ or C-7 position. Notably, the photoaffinity probes linking on the phenol group of the C-3′ position retain excellent activity of inhibiting retinal endothelial cell proliferation with up to 72 nM of GI50
Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization
Eye diseases characterized by excessive angiogenesis such as wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity are major causes of blindness. Cremastranone is an antiangiogenic, naturally occurring homoisoflavanone with efficacy in retinal and choroidal neovascularization models and antiproliferative selectivity for endothelial cells over other cell types. We undertook a cell-based structure–activity relationship study to develop more potent cremastranone analogues, with improved antiproliferative selectivity for retinal endothelial cells. Phenylalanyl-incorporated homoisoflavonoids showed improved activity and remarkable selectivity for retinal microvascular endothelial cells. A lead compound inhibited angiogenesis in vitro without inducing apoptosis and had efficacy in the oxygen-induced retinopathy model in vivo
The antiangiogenic activity of naturally occurring and synthetic homoisoflavonoids from the Hyacinthaceae (sensu APGII)
Excessive blood vessel formation in the eye is implicated in wet age-related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity, which are major causes of blindness. Small molecule antiangiogenic drugs are strongly needed to supplement existing biologics. Homoisoflavonoids have been previously shown to have potent antiproliferative activities in endothelial cells over other cell types. Moreover, they demonstrated a strong antiangiogenic potential in vitro and in vivo in animal models of ocular neovascularization. Here, we tested the antiangiogenic activity of a group of naturally occurring homoisoflavonoids isolated from the family Hyacinthaceae and related synthetic compounds, chosen for synthesis based on structure–activity relationship observations. Several compounds showed interesting antiproliferative and antiangiogenic activities in vitro on retinal microvascular endothelial cells, a disease-relevant cell type, with the synthetic chromane, 46, showing the best activity (GI50 of 2.3 × 10–4 μM)
Ferrochelatase is a therapeutic target for ocular neovascularization
Ocular neovascularization underlies major blinding eye diseases such as “wet” age-related macular degeneration (AMD). Despite the successes of treatments targeting the vascular endothelial growth factor (VEGF) pathway, resistant and refractory patient populations necessitate discovery of new therapeutic targets. Using a forward chemical genetic approach, we identified the heme synthesis enzyme ferrochelatase (FECH) as necessary for angiogenesis in vitro and in vivo. FECH is overexpressed in wet AMD eyes and murine choroidal neovascularization; siRNA knockdown of Fech or partial loss of enzymatic function in the Fechm1Pas mouse model reduces choroidal neovascularization. FECH depletion modulates endothelial nitric oxide synthase function and VEGF receptor 2 levels. FECH is inhibited by the oral antifungal drug griseofulvin, and this compound ameliorates choroidal neovascularization in mice when delivered intravitreally or orally. Thus, FECH inhibition could be used therapeutically to block ocular neovascularization
Reactions of organo-rhodium complexes with multidentate N,N and N,S-heterocycles and exchange studies by NMR
Synthesis and NMR spectral studies of polynuclear complexes of rhodium(I) with bridging benzimidazole derivatives
Reaction of [Rh(diolefin)​(μ-​Cl)​]​2 (diolefin = cycloocta-​1,​5-​diene or norbornadiene) with 2-​substituted benzimidazoles (R = bztH; R = H, Me, Et, Pr or Bu) in the presence of triethylamine yields trinuclear complexes [Rh(diolefin)​(μ-​R-​bzt)​]​3. The latter compds. undergo displacement of diolefin with CO to give tetranuclear complexes [Rh(CO)​2(μ-​R-​bzt)​]​4. NMR spectral studies have been useful in assigning the structures of the complexes
- …